21.04.2022 /
First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)
Personnel Changes in the Management of Eckert & Ziegler AG
Heart repair via neuroimmune crosstalk
